Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix

NCT00601601

Cervical Cancer Precancerous Condition

COMPLETED

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

NCT00049231

Cervical Cancer

COMPLETED NA

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934

Cancer of the Uterine Cervix

COMPLETED

Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia

NCT00511615

Cervical Cancer

COMPLETED

Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples

NCT00629577

Cervical Cancer Precancerous Condition

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.

This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Cervix

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tissue Repository

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data.